Dyskinesia – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Dyskinesia – Pipeline Review, H1 2018’, provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Dyskinesia

– The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects

– The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dyskinesia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Advicenne SA

Amarantus Bioscience Holdings Inc

Avanir Pharmaceuticals Inc

Bionomics Ltd

Cadent Therapeutics

Cavion LLC

Clevexel Pharma SAS

EpiVax Inc

Heptares Therapeutics Ltd

Ipsen SA

IRLAB Therapeutics AB

Medy-Tox Inc

Merz Pharma GmbH & Co KgaA

Neurim Pharmaceuticals Ltd

Neurocrine Biosciences Inc

Neurolixis Inc

Phenomenome Discoveries Inc

Sage Therapeutics Inc

SciFluor Life Sciences LLC

SOM Biotech SL

Synchroneuron Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Dyskinesia Overview 6

Dyskinesia Therapeutics Development 7

Dyskinesia Therapeutics Assessment 16

Dyskinesia Companies Involved in Therapeutics Development 25

Dyskinesia Drug Profiles 35

Dyskinesia Dormant Projects 141

Dyskinesia Discontinued Products 143

Dyskinesia Product Development Milestones 144

Appendix 154

List of Tables

List of Tables

Number of Products under Development for Dyskinesia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Dyskinesia Pipeline by Adamas Pharmaceuticals Inc, H1 2018

Dyskinesia Pipeline by Addex Therapeutics Ltd, H1 2018

Dyskinesia Pipeline by Advicenne SA, H1 2018

Dyskinesia Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Dyskinesia Pipeline by Avanir Pharmaceuticals Inc, H1 2018

Dyskinesia Pipeline by Bionomics Ltd, H1 2018

Dyskinesia Pipeline by Cadent Therapeutics, H1 2018

Dyskinesia Pipeline by Cavion LLC, H1 2018

Dyskinesia Pipeline by Clevexel Pharma SAS, H1 2018

Dyskinesia Pipeline by EpiVax Inc, H1 2018

Dyskinesia Pipeline by Heptares Therapeutics Ltd, H1 2018

Dyskinesia Pipeline by Ipsen SA, H1 2018

Dyskinesia Pipeline by IRLAB Therapeutics AB, H1 2018

Dyskinesia Pipeline by Medy-Tox Inc, H1 2018

Dyskinesia Pipeline by Merz Pharma GmbH & Co KgaA, H1 2018

Dyskinesia Pipeline by Neurim Pharmaceuticals Ltd, H1 2018

Dyskinesia Pipeline by Neurocrine Biosciences Inc, H1 2018

Dyskinesia Pipeline by Neurolixis Inc, H1 2018

Dyskinesia Pipeline by Phenomenome Discoveries Inc, H1 2018

Dyskinesia Pipeline by Sage Therapeutics Inc, H1 2018

Dyskinesia Pipeline by SciFluor Life Sciences LLC, H1 2018

Dyskinesia Pipeline by SOM Biotech SL, H1 2018

Dyskinesia Pipeline by Synchroneuron Inc, H1 2018

Dyskinesia Dormant Projects, H1 2018

Dyskinesia Dormant Projects, H1 2018 (Contd..1), H1 2018

Dyskinesia Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Dyskinesia, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports